iTeos Therapeutics’ (ITOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a report released on Thursday,Benzinga reports. They currently have a $21.00 price objective on the stock.

A number of other equities analysts have also weighed in on the stock. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Friday, January 10th. Wells Fargo & Company lowered their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th.

iTeos Therapeutics Trading Down 0.4 %

NASDAQ ITOS opened at $7.74 on Thursday. iTeos Therapeutics has a 12 month low of $7.09 and a 12 month high of $18.75. The stock’s fifty day moving average price is $8.05 and its 200-day moving average price is $11.61. The stock has a market cap of $282.74 million, a P/E ratio of -2.46 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Matthew Gall bought 5,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On iTeos Therapeutics

Large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its holdings in shares of iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock worth $164,000 after buying an additional 690 shares during the last quarter. Creative Planning boosted its stake in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after acquiring an additional 1,196 shares during the last quarter. nVerses Capital LLC grew its position in shares of iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new position in iTeos Therapeutics in the 3rd quarter worth $31,000. 97.16% of the stock is currently owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.